Biofrontera Inc.: A Compelling Investment in Dermatology
September 7, 2025
Biotechnology
-
-
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
August 18, 2025
-
FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet’s Disease after Reviewing Recent Phase 2 Clinical Study Results
August 18, 2025
-
Equillium Announces Up to $50 Million Financing to Advance EQ504, a Novel Aryl Hydrocarbon Receptor Modulator, into the Clinic
August 11, 2025
-
Aditxt and Crypto.com Sign Agreement for Custodial Crypto Account, Announce ADTX Share Access on Crypto.com as Part of the Larger bitXbio(TM) Initiative
August 11, 2025
-
Bioxytran’s Breakthrough Broad-Spectrum Antiviral Technology Poised to Revolutionize Respiratory Infection Treatment
August 7, 2025
-
Tevogen Receives $1 Million to Accelerate AI-Driven Drug Discovery; Remains Well Capitalized to Execute Growth Strategy
August 7, 2025
-
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
August 7, 2025
-
Equillium Announces Strategic Expansion of Cryptocurrency Treasury Reserve Strategy
August 4, 2025
-
180 Life Sciences Announce an Upsized $425 Million Private Placement to Establish an Ether Treasury Reserve Led by Consortium of Digital Asset Leaders to Launch ETHZilla
July 29, 2025
-
AscellaHealth HUB Partnership with Abeona Therapeutics® Supports Launch Success of Novel Cell-Based Gene Therapy and Access to Treatment for Rare Disease Patients
July 29, 2025
-
Hyperion DeFi Purchases Additional $5 Million in HYPE for Kinetiq iHYPE Strategy
July 28, 2025
-
Windtree Therapeutics Announces Up To $520 Million in New Funding to Amplify BNB Cryptocurrency Treasury Strategy
July 24, 2025
-
Hemostemix Closes $2,969,600 Private Placement
July 24, 2025
-
Kraken and Windtree Therapeutics Announce Strategic Partnership for BNB Custody, Trading, and OTC Services
July 22, 2025
-
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
July 21, 2025